ACA
AERI

Avoro Capital Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

Avoro Capital Advisors’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-230,842
Closed -$12.1M – 52
2017
Q2 		$12.1M Sell
230,842
-194,158
-46% -$9.04M 1.53% 20
2017
Q1 		$19.3M Sell
425,000
-185,000
-30% -$8.25M 2.46% 15
2016
Q4 		$23.1M Buy
610,000
+110,000
+22% +$4.16M 4.66% 9
2016
Q3 		$18.9M Buy
+500,000
New +$11M 3.31% 13

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avoro Capital Advisors's AERI Position: Q3 2017 in Review

Avoro Capital Advisors sold out of Aerie Pharmaceuticals (AERI) in Q3 2017, closing a stake of 230,842 shares — an estimated $12.1M sold.

Avoro Capital Advisors first reported a position in AERI in Q3 2016 and held it in 4 quarters. The position peaked at $23.1M in Q4 2016. 182 funds tracked by Wall St. Rank hold AERI as of Q3 2017.

  • Avoro Capital Advisors reported no remaining Aerie Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Avoro Capital Advisors sold 230,842 Aerie Pharmaceuticals shares in Q3 2017, an estimated $12.1M.
  • Avoro Capital Advisors first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 4 quarters.
  • Avoro Capital Advisors's Aerie Pharmaceuticals position peaked at $23.1M in Q4 2016.
  • 182 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2017.

Based on Avoro Capital Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.